Evidence map›Paper›PMID 42422202›Full record

ArticleFrontiers in neurology

Long-term efficacy of neural circuit blockade for treating blepharospasm: a retrospective case series study.

Gang Liu, Qiangying Guo, Jie Xiang, Zhen Xu, Suying Chen, Yanling Xue, Zhitao Liu, Huixia Jin, Shangyi Yu, Ting Jiao and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Gang LiuMeige Syndrome Center, The Third People's Hospital of Henan Province, Zhengzhou, China.
Qiangying GuoMeige Syndrome Center, The Third People's Hospital of Henan Province, Zhengzhou, China.
Jie XiangMeige Syndrome Center, The Third People's Hospital of Henan Province, Zhengzhou, China.
Zhen XuMeige Syndrome Center, The Third People's Hospital of Henan Province, Zhengzhou, China.
Suying ChenMeige Syndrome Center, The Third People's Hospital of Henan Province, Zhengzhou, China.
Yanling XueMeige Syndrome Center, The Third People's Hospital of Henan Province, Zhengzhou, China.
Zhitao LiuMeige Syndrome Center, The Third People's Hospital of Henan Province, Zhengzhou, China.
Huixia JinMeige Syndrome Center, The Third People's Hospital of Henan Province, Zhengzhou, China.
Shangyi YuMeige Syndrome Center, The Third People's Hospital of Henan Province, Zhengzhou, China.
Ting JiaoMeige Syndrome Center, The Third People's Hospital of Henan Province, Zhengzhou, China.
Xia ChenMeige Syndrome Center, The Third People's Hospital of Henan Province, Zhengzhou, China.
Zhenzhen LiuMeige Syndrome Center, The Third People's Hospital of Henan Province, Zhengzhou, China.
Xiangying XiMeige Syndrome Center, The Third People's Hospital of Henan Province, Zhengzhou, China.
Yanhong LiMeige Syndrome Center, The Third People's Hospital of Henan Province, Zhengzhou, China.
Lili ShangMeige Syndrome Center, The Third People's Hospital of Henan Province, Zhengzhou, China.
Jiao DuMeige Syndrome Center, The Third People's Hospital of Henan Province, Zhengzhou, China.
Xianzhong LiuMeige Syndrome Center, The Third People's Hospital of Henan Province, Zhengzhou, China.
Shihui WeiSenior Department of Ophthalmology, The Chinese People's Liberation Army General Hospital, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Blepharospasm is a common symptom of Meige syndrome and often leads to functional blindness. Although current treatment options, such as oral medications, botulinum toxin injections, resection of periocular muscles, and deep brain stimulation, are available, no definitive method effectively eliminates blepharospasm. Objective: To address this unmet need, we developed a novel approach-neural circuit blockade (NCB). This study aimed to analyse its long-term efficacy for blepharospasm. Methods: NCB eliminates trigeminal nerve stimulation by facial expression muscles, reducing the production and input of sensory information, weakening feedback-based and plastic motor information functions, decreasing orbicularis oculi muscle tension, and alleviating blepharospasm. A retrospective analysis was conducted on 570 patients who underwent NCB treatment, with a median postoperative follow-up of 51 months. Therapeutic efficacy was evaluated by comparing preoperative and postoperative scores on the Shorr blepharospasm grading scale, Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS-M), and Blepharospasm Disability Index (BSDI). Results: Based on the Shorr grading scale, preoperatively, 97.9% of patients were grade 4, whereas 2.1% were grade 3. Postoperatively, 87.5% achieved complete remission (grade 0), whereas 7.4, 3.7, 0.9, and 0.5% were grades 1, 2, 3, and 4, respectively. Pre- and postoperative BFMDRS-M scores significantly differed: eye (8.0 vs. 0.0), mouth (3.0 vs. 0.0), speech/swallowing (3.0 vs. 2.0), neck (3.0 vs. 1.5), and total (8.0 vs. 0.0). BSDI scores also significantly differed pre- and postoperatively. The results indicate that NCB effectively alleviates blepharospasm and addresses the lack of a definitive treatment, without causing severe local or systemic complications such as facial paralysis. Conclusion: NCB can safely and effectively alleviate blepharospasm, improve quality of life, and demonstrate stable long-term efficacy.

Indexed as

blepharospasmlong-term efficacyMeige syndromeneural circuit blockaderetrospective study

Identifiers

PMID42422202
PMCPMC13341525

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.